Study details
Enrolling now
AT1001 Trial for Long COVID
Massachusetts General Hospital
NCT IDNCT05747534ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
150
Study length
about 3.8 years
Ages
7–50
Locations
2 sites in MA
About this study
This trial is testing Larazotide Acetate (AT1001) versus a placebo in people with Long COVID. Participants will take AT1001 or the placebo four times a day for 21 days, and it will last about 1400 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Larazotide Acetate
- 2.Take Placebo
PhasePhase 2
Primary goalAdverse Event Profiling and Time to Symptom Resolution
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low9%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Adverse Event Profiling and Time to Symptom Resolution
Secondary: Cytokine profiling, Antigen Testing and Humoral and Cellular Responses
Body systems
Infectious